Somatic cells can be reprogrammed into iPSCs by the enforced expression of defined transcription factor combinations, such as Oct4, Klf4, Sox2 and c-Myc (OKSM) 1 . As iPSCs can differentiate into virtually any somatic cell type, they provide an invaluable tool for the study of development and disease 2 . Recent reports have suggested that, compared to blastocyst-derived embryonic stem cells (ESCs), iPSCs harbor genetic and epigenetic abnormalities, including the dysregulation of imprinted genes, gene copy-number variations, the accumulation of point mutations and aberrant methylation patterns 3 . To harness the full potential of iPSC technology, it is important to understand the mechanisms underlying these aberrations and to find ways to prevent them.
We have previously used microarrays to show that RNA expression patterns in ESCs and iPSCs are essentially indistinguishable, with the exception of a few maternally expressed non-coding transcripts (for example, Meg3 (also known as Gtl2) and Rian) and microRNAs (miRNAs) originating from the imprinted Dlk1-Dio3 gene cluster 4 that is silenced in the majority of iPSC lines 5 . We call iPSC lines that showed aberrant silencing of Dlk1-Dio3 transcripts Meg3 off iPSCs and cell lines with ESC-like expression Meg3 on iPSCs. In accordance with developmental defects seen in mutant mice where the Dlk1-Dio3 cluster is affected 4, 6 , Meg3 off iPSCs failed to yield viable all-iPSC mice after tetraploid (4N) blastocyst injections 5, 7 , which constitutes the most stringent assay for developmental potential. On the basis of these results, we conclude that the stable repression of maternal Dlk1-Dio3 transcripts acts as a roadblock for the establishment of full pluripotency in iPSCs.
In this manuscript, we offer new insights into the molecular mechanisms of aberrant Dlk1-Dio3 silencing in iPSCs and provide an efficient way to prevent it by supplementing reprogramming cultures with ascorbic acid. We further demonstrate the utility of this approach by generating entirely iPSC-derived monoclonal mice from terminally differentiated B lymphocytes.
RESULTS

Dlk1-Dio3 hypermethylation occurs late and requires Dnmt3a
We first determined the kinetics of Meg3 expression by analyzing defined purified reprogramming intermediates 8 obtained from mouse embryonic fibroblasts (MEFs) carrying a transgenic reprogramming system 9 (Fig. 1a) . The study of intermediate populations, which are enriched for cells that will form iPSCs, was critical because of the low overall efficiency of reprogramming. Analysis of these intermediates showed rapid downregulation of Meg3 RNA following OKSM expression, concurrent with extinction of the fibroblast marker gene Fbn2 but before activation of the endogenous pluripotency genes Nanog and Pou5f1 (the official Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells The generation of induced pluripotent stem cells (iPSCs) often results in aberrant epigenetic silencing of the imprinted Dlk1-Dio3 gene cluster, compromising the ability to generate entirely iPSC-derived adult mice ('all-iPSC mice'). Here, we show that reprogramming in the presence of ascorbic acid attenuates hypermethylation of Dlk1-Dio3 by enabling a chromatin configuration that interferes with binding of the de novo DNA methyltransferase Dnmt3a. This approach allowed us to generate all-iPSC mice from mature B cells, which have until now failed to support the development of exclusively iPSC-derived postnatal animals. Our data show that transcription factor-mediated reprogramming can endow a defined, terminally differentiated cell type with a developmental potential equivalent to that of embryonic stem cells. More generally, these findings indicate that culture conditions during cellular reprogramming can strongly influence the epigenetic and biological properties of the resultant iPSCs.
A r t i c l e s symbol for Oct4) (Fig. 1b) . In contrast to the early downregulation of Meg3, abnormal hypermethylation of CpG dinucleotides within the intergenic differentially methylated region (IG-DMR), which correlates with stable gene silencing of maternally encoded transcripts 4 , was only seen at later reprogramming stages. In wild-type somatic cells and ESCs, ~50% of the IG-DMRs were methylated, reflecting the silenced and completely methylated paternal copy of Dlk1-Dio3. Of note, the timing of IG-DMR hypermethylation coincided with the demethylation of the endogenous Pou5f1 promoter (Fig. 1c) , which is an indicator of successful epigenetic reprogramming to pluripotency 2 . Therefore, repression of maternal Dlk1-Dio3 transcripts seems to occur in two distinct waves, with transcriptional downregulation preceding the acquisition of aberrant DNA methylation and stable gene silencing.
During male germ cell development, the IG-DMR is methylated by the de novo DNA methyltransferase Dnmt3a to establish an imprint that is maintained throughout adulthood 10 . Additionally, the nonenzymatic protein Dnmt3l has been implicated in Dlk1-Dio3 imprinting, although its involvement in this process remains controversial [10] [11] [12] .
To genetically test whether Dnmt3a and Dnmt3l are responsible for the hypermethylation observed in iPSCs, we reprogrammed MEFs lacking either Dnmt3a 10 or Dnmt3l 12 (Fig. 1d) . The majority of resultant Dnmt3a-deficient iPSC clones showed normal (40-50%) methylation levels at both the IG-DMR and at a second DMR proximal to the Meg3 promoter termed the Meg3 DMR 4 , indicating that Dnmt3a catalyzes the hypermethylation seen in Meg3 off iPSCs (Fig. 1e) . As expected, Dnmt3a-deficient iPSC clones had higher Meg3 transcript levels compared to control cells ( Fig. 1f and Supplementary Fig. 1a) .
In contrast, Dnmt3l-deficient iPSCs had, on average, only a small decrease in methylation levels and a less pronounced increase in Meg3 expression (Fig. 1e,f and Supplementary Fig. 1b) . Taken together, these results provide genetic evidence that Dnmt3a is essential for Dlk1-Dio3 hypermethylation during the generation of Meg3 off iPSCs, whereas Dnmt3l promotes this process. The observation that rare Dnmt3a-deficient iPSC clones (2 of 15) exhibited slightly elevated DNA methylation levels at the IG-DMR (Supplementary Fig. 1a ) and expressed reduced amounts of Meg3 RNA might be explained by delayed Cre-mediated excision of Dnmt3a during reprogramming or by an alternative mechanism of gene silencing.
Serum replacement and ascorbic acid prevent Meg3 silencing
We next sought to identify an efficient and safe approach to prevent Dlk1-Dio3 silencing that does not depend on genetic interference with Dnmt3a by testing alternative iPSC derivation protocols. Specifically, we evaluated the effects of omitting feeder cells or using serum replacement (SR) medium 13 instead of fetal bovine serum (FBS)-containing medium during reprogramming (Fig. 2a) . The majority of iPSCs derived in FBScontaining medium in the presence or absence of feeders expressed only residual levels of Meg3 (11 of 12 and 6 of 9 clones, respectively) (Fig. 2b) , indicating that feeders do not substantially influence the outcome of Dlk1-Dio3 silencing. Unexpectedly, however, eight of nine iPSC clones produced with SR medium and all six iPSC clones derived in a mixture of FBS and SR media expressed normal levels of Meg3, indicating that SR medium contains a dominant activity that prevents the silencing of Dlk1-Dio3 that is normally incurred with FBS (Fig. 2b,c) . A r t i c l e s SR medium contains ascorbic acid (also known as vitamin C), which has been shown to influence DNA methylation patterns in human ESCs 14 and may thus be responsible for inhibiting aberrant Dlk1-Dio3 silencing. Indeed, addition of ascorbic acid to FBScontaining medium during MEF reprogramming abrogated hypermethylation of the IG-DMR and Meg3 DMR and maintained normal expression levels of Meg3 in a concentration-dependent manner (Fig. 2d,e and Supplementary Fig. 2 ). Consistent with a previous report 15 , exposure of cells expressing OKSM to ascorbic acid also substantially increased reprogramming efficiencies (from 0.5-1% to ~4%) and speed (5 d of OKSM expression were sufficient to generate doxycycline-independent colonies) ( Supplementary Fig. 3 ).
Ascorbic acid and alternative reprogramming strategies
Recent reports have documented roles for exogenous c-Myc expression 16, 17 and reprogramming factor stoichiometry 18 in the outcome of Dlk1-Dio3 imprinting in iPSCs, suggesting that ascorbic acid may prevent Meg3 silencing by modulating these parameters. However, all nine MEF-derived iPSC (MEF-iPSC) lines generated by exogenous expression of only three factors (OKS) in the absence of ascorbic acid showed hypermethylation of the IG-DMR and Meg3 DMR (Supplementary Fig. 4 ). We were also unable to find measurable differences in total or relative protein levels of OKSM factors between ascorbic acid-treated and untreated reprogrammable MEFs (Supplementary Fig. 3c ) and therefore conclude that ascorbic acid prevents Dlk1-Dio3 silencing independently of reprogramming factor levels and stoichiometry.
We confirmed the recent observation that the reprogramming of MEFs using an alternative polycistronic cassette (OSKM) that produces the four reprogramming factors at different stoichiometries, compared with our system (OKSM), gives rise to fewer Meg3 off iPSCs 18 (Supplementary Fig. 5 ). In directly comparing these two transgenic systems, we made additional observations that are worth mentioning here. First, the efficiency of MEF-iPSC formation with the alternative OSKM system was substantially lower (by at least one order of magnitude; Supplementary Fig. 5a ), raising the possibility that the two systems might have reprogrammed different subsets of cells that are present in heterogeneous fibroblast cultures. Second, we noticed that the majority of bone marrow-derived iPSC clones that were reprogrammed with either transgenic system showed hypermethylation of the IG-DMR and Meg3 DMR (6 of 8 clones with OKSM and 15 of 18 with OSKM), suggesting that factor stoichiometry was either suboptimal in those bone marrow cells that gave rise to iPSCs or pointing to a cell type-specific effect on Dlk1-Dio3 silencing that is independent of factor stoichiometry ( Supplementary Fig. 5c,d ). Treatment of bone marrow cells undergoing reprogramming with OSKM with ascorbic acid also prevented aberrant silencing in the majority of resultant iPSC clones (7 of 8). Lastly, several MEF-iPSC clones derived with the OSKM transgene (7 of 18) had hypomethylation (<30% of CpGs methylated) of both the IG-DMR and Meg3 DMR, irrespective of the presence of ascorbic acid (Supplementary Fig. 5b ). The biological relevance of this observation remains unclear.
Of note, all seven MEF-iPSC clones generated with four individual lentiviral vectors 8 showed IG-DMR hypermethylation in the absence of ascorbic acid, which could be prevented by addition of the compound (Supplementary Fig. 6 ). This result indicates that Dlk1-Dio3 silencing is not a peculiarity of the polycistronic construct used in our study but rather is a general phenomenon during iPSC derivation in conventional culture conditions. 
Specificity of ascorbic acid treatment
MEF-iPSCs generated with or without ascorbic acid showed complete DNA demethylation and acquisition of the activating histone H3 lysine 4 trimethylation (H3K4me3) chromatin mark at the Pou5f1 promoter (Supplementary Fig. 7) , indicating that epigenetic remodeling of this key pluripotency gene is not affected by ascorbic acid treatment. We also failed to detect differences in the methylation levels of other imprinted genes, including the paternally imprinted H19 and Rasgrf1 genes and the maternally imprinted Mest and Peg3 genes ( Supplementary Fig. 8a,b) , thereby showing that ascorbic acid does not globally affect imprinted gene methylation. Following retinoic acid exposure, ascorbic acid-treated iPSC clones upregulated Dlk1 to levels similar to those seen in ESCs (Supplementary Fig. 8c) , showing appropriate transcriptional control of the Dlk1-Dio3 locus upon differentiation. Lastly, in global gene expression profiling, the expression status of maternal Dlk1-Dio3 transcripts was the only discernible difference between clones derived in the presence and absence of ascorbic acid (Fig. 2f) , suggesting that the addition of this compound during reprogramming does not have lasting effects on the expression of other genes in cells that are in the pluripotent state.
To test whether treatment with ascorbic acid derepresses the normally silenced paternally inherited allele of Meg3 and causes a switch of imprinted alleles, we derived iPSCs from Mus musculus × Mus castaneus hybrid fibroblasts that carry a SNP in the paternal allele of Meg3 (Supplementary Fig. 9a ). All nine Meg3 on iPSCs clones analyzed expressed only the maternal Meg3 allele (Supplementary Fig. 9b,c) , which is indicative of imprint stability at the Dlk1-Dio3 locus.
The exposure of established Meg3 off iPSCs to ascorbic acid for fifteen passages was insufficient to reverse silencing, as shown by sustained hypermethylation of both the IG-DMR and Meg3 DMR (Supplementary Fig. 10 ). These observations show that ascorbic acid treatment prevents but cannot reverse aberrant DNA methylation of the Dlk1-Dio3 locus.
Ascorbic acid preserves active chromatin marks at Dlk1-Dio3
To gain insights into the mechanism by which ascorbic acid might counteract epigenetic silencing of Dlk1-Dio3, we isolated reprogramming intermediates from MEFs derived either in the presence or absence of the compound and analyzed histone modifications at the IG-DMR that have previously been correlated with DNA methylation. Intermediates generated in medium with FBS alone rapidly lost the activating marks of histone H3 acetylation and histone H3 lysine 4 dimethylation (H3K4me2) and failed to gain H3K4me3 ( Fig. 3 and Supplementary  Fig. 11a ), a modification seen in ESCs and Meg3 on iPSCs but not in MEFs and Meg3 off iPSCs. In contrast, ascorbic acid-treated intermediates maintained H3K4me2 and histone H3 acetylation and gained H3K4me3 at the IG-DMR during reprogramming, with levels ultimately being comparable to those seen in ESCs (Fig. 3b,c and Supplementary  Fig. 11a ). We did not detect significant differences in the repressive H3 lysine 27 trimethylation (H3K27me3) mark in intermediates in the presence or absence of ascorbic acid or in established pluripotent cell lines (Supplementary Fig. 11b) . Thus, ascorbic acid treatment preserves an active histone configuration at Dlk1-Dio3, which is frequently lost in regular FBS-containing reprogramming conditions.
To correlate the observed changes in histone modification at Dlk1-Dio3 with DNA methylation patterns, we determined methylation levels at the IG-DMR in the same reprogramming intermediates. This analysis showed that untreated fibroblasts undergoing reprogramming 
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become progressively hypermethylated at later reprogramming stages, whereas ascorbic acid-treated intermediates maintain normal DNA methylation levels throughout the process ( Fig. 3d; see also Fig. 1c) . Of note, aberrant DNA hypermethylation coincided with increased binding of Dnmt3a to the IG-DMR in late reprogramming intermediates in the absence of ascorbic acid (Fig. 3e) , which is consistent with the previous observation that Dnmt3a can only recognize unmodified histone H3 lysine 4 (H3K4) tails 19, 20 . We failed to detect increased expression of DNA methyltransferase genes in untreated intermediates, thus ruling out the possibility that hypermethylation is the consequence of transcriptional upregulation of these enzymes (Supplementary Fig. 12 ). Ascorbic acid has antioxidative activity, which may be critical for its inhibitory effect on Dlk1-Dio3 hypermethylation. However, the majority of iPSC clones derived under reduced-oxygen conditions or in the presence of the alternative antioxidant resveratrol still showed IG-DMR hypermethylation (Supplementary Fig. 13) , thus arguing against a role for the antioxidative properties of ascorbic acid in preventing Dlk1-Dio3 silencing. It is possible, though, that exposure to other antioxidative agents may have similar effects as ascorbic acid treatment on the Dlk1-Dio3 locus. Taken together, these observations suggest that the rapid loss of activating histone marks in the absence of ascorbic acid facilitates the recruitment of Dnmt3a to the IG-DMR, allowing Dnmt3a to catalyze DNA hypermethylation and leading to stable epigenetic silencing of maternal Dlk1-Dio3 transcripts (see model in Fig. 3f ).
Meg3 on iPSCs derived from mature B cells
To evaluate whether ascorbic acid treatment facilitates the generation of Meg3 on iPSCs from a defined, terminally differentiated cell type, These are the same genes as reported in e, excluding the 12,618 genes common to all three groups. The side bar shows genes that were enriched for H3K4me3 in ESC1 only (blue bar, 212 genes) or in both B-iPSC clones only (red bar, 213 genes). Gaussian-smoothed read density enrichment is shown over input samples in log 2 scale. For each gene, the maximum enrichment across all of the samples was used to compute a scaling factor to set the maximum value equal to 10.
we isolated CD19 + B cells from the spleens of adult reprogrammable mice 9 and cultured them in doxycycline-containing medium in the presence or absence of ascorbic acid for 14 d until iPSC colonies emerged ( Fig. 4a and Supplementary Fig. 14) . The efficiency of formation of iPSCs from mature B cells (B-iPSCs) ranged between 0.02% and 0.06% in the presence of ascorbic acid and between 0.01% and 0.05% in the absence of ascorbic acid (data not shown), representing a less dramatic increase in reprogramming efficiency following ascorbic acid treatment than that seen in fibroblasts ( Supplementary  Fig. 3a) . Whereas all 36 B-iPSCs generated without ascorbic acid exhibited aberrant hypermethylation of the IG-DMR and Meg3 DMR and/or diminished Meg3 transcript levels, 4 of 17 iPSC clones (24%) established in a mixture of FBS and SR media and 5 of 11 clones (45%) derived in the presence of ascorbic acid showed normal DNA methylation patterns and expressed Meg3 at ESC-like levels ( Fig. 4b and Supplementary Fig. 15 ). The lower frequency with which Meg3 on B-iPSCs were obtained relative to MEF-iPSCs might be due to the higher baseline methylation levels of the IG-DMR in B lymphocytes and the extremely low expression levels of Meg3 in these cells (Supplementary Fig. 16 ). Meg3 on B-iPSCs showed typical ESC-like morphology, homogenously expressed endogenous pluripotency markers (Fig. 4c) , exhibited DNA demethylation and enrichment for H3K4me3 at the Pou5f1 promoter and had a predominantly normal karyotype (Supplementary Fig. 17) . Collectively, these data show that ascorbic acid treatment efficiently preserves normal genomic imprinting at Dlk1-Dio3 during the reprogramming of a defined, terminally differentiated non-fibroblast cell type.
Given that H3K4me3 deposition at the Dlk1-Dio3 locus in reprogramming intermediates was strongly affected by ascorbic acid treatment (see Supplementary Fig. 11a ), we wondered whether H3K4me3 patterns might be altered on a genome-wide scale in iPSCs by this compound. To examine this possibility, we performed chromatin immunoprecipitation combined with sequencing (ChIP-seq) for the H3K4me3 modification in two B-iPSC clones derived in the presence of ascorbic acid (Meg on and Meg3 off , respectively) and one fully pluripotent ESC line 5 that had never been exposed to ascorbic acid. Bioinformatic analysis of sequenced reads from these clones confirmed the absence of the activating H3K4me3 modification at the Meg3 locus in the Meg3 off clone, whereas pluripotency loci such as Nanog and Pou5f1 were similarly enriched for H3K4me3 in all pluripotent cell lines (Fig. 4d) . Both B-iPSC clones showed a very high degree of overlap in global H3K4me3 patterns (>95%) compared with the control ESC line (Fig. 4e,f) . ChIPseq results from our pluripotent cell lines also showed a large overlap with a previously published data set of genome-wide H3K4me3 patterns in ESCs 21 ( Fig. 4d and Supplementary Fig. 18 ), further suggesting that ascorbic acid exposure does not cause major global epigenetic aberrations, at least for this key epigenetic mark. It remains to be tested whether the few detected differences among the various samples ( Fig. 4f and Supplementary Table 1 ) are truly the result of ascorbic acid exposure or instead were caused by line-to-line variation, as has been seen before among pluripotent cell lines 22 .
All-iPSC mice generated from mature B cells Lastly, we tested the developmental potential of B-iPSCs derived in the presence of ascorbic acid by 4N-embryo complementation 23, 24 (Fig. 5a ). It should be noted that adult all-iPSC mice have thus far only been produced from fibroblast populations, whereas attempts to produce 4N complementation-competent mice from defined adult cell types, such as neural progenitor cells 25 or lymphocytes 26 , have been unsuccessful, likely because of embryonic growth arrest at midgestation 25 . Notably, all four Meg3 on B-iPSC clones tested with this rigorous assay gave rise to neonatal all-iPSC mice, whereas the two Meg3 off clones tested only yielded late-stage resorptions ( Table 1 ). Given that Meg3-null animals die pre-or perinatally 6 , our results do not exclude the possibility that rare Meg3 off all-iPSC mice can develop as far as full term before they succumb, which would be consistent with a recent report 18 . We confirmed that viable animals were entirely derived from B-iPSCs by PCR for strain-specific polymorphisms ( Fig. 5b) and by Southern blot analysis that detected clonal rearrangements of the immunoglobulin heavy chain locus (Fig. 5c) . All-iPSC neonates generated from three of the four Meg3 on clones survived for at least several days, and animals derived from two of the clones reached adulthood and exhibited uniform agouti coat color ( Fig. 5d and Table 1 ). Peripheral B cells isolated from an adult all-B-iPSC mouse expressed immunoglobulins composed of essentially only κ light chain on their surface (Fig. 5e) , whereas B cells from control mice produced immunoglobulins with both κ and λ light chains, further supporting the monoclonal origin of B cells in mice derived from B-iPSCs. We also obtained agouti offspring from all-B-iPSC mice, demonstrating successful germline transmission (Fig. 5f) . These data show that Meg3 on iPSCs produced from terminally differentiated B cells can support the development of entirely iPSC-derived adult monoclonal mice.
DISCUSSION
Herein, we have shown that ascorbic acid treatment efficiently preserves a normal imprinting status at the Dlk1-Dio3 gene cluster during the derivation of mouse iPSCs from different adult cell types and using various means of reprogramming factor expression. Our data suggest that ascorbic acid inhibits Dlk1-Dio3 silencing by interfering with OKSM-induced loss of H3K4 methylation at the maternal IG-DMR by a mechanism that is yet to be identified. Sustained H3K4 methylation then prevents the recruitment of Dnmt3a, which is essential for Dlk1-Dio3 DNA hypermethylation. Unexpectedly, iPSC lines derived in the presence of ascorbic acid did not have detectable changes in transcript levels outside of the Dlk1-Dio3 cluster, altered DNA methylation patterns at a number of additional imprinted genes or major differences in genome-wide H3K4me3 occupancy relative to untreated cells, suggesting a remarkable specificity for ascorbic acid. However, it is possible that ascorbic acid influences other chromatin marks in iPSCs that do not adversely affect iPSC developmental potential as measured by their ability to generate adult all-iPSC mice. Given its strong effect on reprogramming speed and efficiency, it is conceivable that ascorbic acid introduces widespread but transient alterations in chromatin that are resolved upon entry into a pluripotent state and, hence, are undetectable in established iPSCs.
It is noteworthy that a recent report connected ascorbic acid with the H3K36 demethylase Kdm2b during iPSC formation 27 . It should thus be informative to test whether Kdm2b may also be involved in preventing Dlk1-Dio3 silencing. Furthermore, the maternally expressed miRNA mir-369 encoded within the Dlk1-Dio3 cluster has recently been suggested to reprogram fibroblasts into iPSCs in combination with other select miRNAs 28 , raising the possibility that ascorbic acid may in part increase reprogramming efficiency by maintaining normal Dlk1-Dio3 imprinting.
Addition of ascorbic acid to cells undergoing reprogramming allowed us to derive Meg3 on iPSCs from mature B cells, which supported the development of adult all-iPSC mice. To our knowledge, this is the first demonstration that full developmental potential can be reinstated in iPSCs produced from a terminally differentiated adult cell of defined origin. Although we were unable to generate Meg3 on B-iPSC clones in the absence of ascorbic acid using our reprogrammable system, we cannot rule out the possibility that alternative reprogramming cocktails or constructs might facilitate their derivation in standard conditions. Also, our observation that adult all-iPSC animals could not be obtained from every Meg3 on B-iPSC clone tested indicates that normal expression of Dlk1-Dio3 alone is a valuable indicator but not an absolute predictor for postnatal survival of all-iPSC mice. This finding further implies that other cell line-specific epigenetic and/or genetic abnormalities may be present in iPSCs, which should be identifiable with deep sequencing approaches.
The ability to generate all-iPSC animals from single B lymphocytes might provide an efficient way to produce monoclonal mice with desired antibody specificities for immunological studies. Our observations should also help to streamline the production of mouse iPSCs with increased efficiency and fidelity from different cell types. In this context, it will be important to evaluate whether the expression status of Meg3 correlates with other transcriptional, epigenetic or genetic features of iPSCs that have escaped detection with the assays employed thus far. More generally, we made the unexpected observation that alterations of environmental conditions during cellular reprogramming can have profound effects on the epigenetic and biological properties of derivative pluripotent cell lines. These data may therefore also have ramifications for ongoing comparative studies between ESCs and iPSCs as well as for disease modeling approaches.
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